EDP Biotech has been busy since the company took the stage at Startup Day 2019, by now offering COVID-19 antibody testing.

You likely remember Eric Mayer, as he is the CEO of EDP Biotech, a medical device company whose mission is the development and commercialization of in-vitro diagnostic tests that detect disease early. EDP’s platform technology utilizes machine learning and multiplexing to simultaneously measure numerous proteins from a single blood draw.

EDP was planning on launching its first multi-marker blood test from the platform, ColoPlex™, used in the early detection of colorectal cancer and presenting some new data at upcoming conferences when the coronavirus hit.

Facing uncertainty and the added stress of finding out some of his own family members were diagnosed with the coronavirus, Mayer dedicated himself to learning as much as possible. In conversations with doctors across the state, he recognized the need for widespread antibody testing.

EDP’s facility and lab was recently added as one of a few entities on the U.S. Food and Drug Administration’s website as a commercial testing lab and manufacturer of COVID-19 serology (antibody) tests.

With this announcement, EDP has started developing the tools needed to build, scale and validate tests here in Tennessee. The company is also hiring medical technicians to be able to deliver testing services to Tennessee as the economy reopens.

EDP has begun performing a modest 100 antibody tests a day for researchers, with the hopes of potentially performing three to four thousand tests a day for patients across Tennessee pending further regulatory approvals.

The company has since opened its CLIA laboratory, and they can now begin taking reservations for COVID-19 antibody testing. You can browse through their website for antibody test facts and other important details.

Once the test has received its final FDA authorization, EDP will contact you directly with next steps to finish your test order and receive your at-home finger stick blood collection kit in the mail.